Sarepta receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sarepta Therapeutics Inc (SRPT)
The Sarepta share price today is 16.78, view NASDAQ SRPT stock exchange data. Track the latest Sarepta share price with real-time updates on SRPT stock performance including market cap, day range, 52-week range and dividend yield. Access SRPT charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.47
17.26
52 wk Range
14.68
25.32
SRPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.4717.26
52 wk Range
14.6825.32
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SRPT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
22.09
Upside
+31.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Form 4 Sarepta Therapeutics Inc For: 29 July- Investing.com
- Sarepta receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
11 Hold
5 Sell
Ratings:
24 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 22.09
(+31.63% Upside)
Sarepta Therapeutics Inc SWOT Analysis
Gene Therapy Setbacks | Delve into Sarepta's challenges with Elevidys, including safety concerns and regulatory hurdles, impacting its market position and financial outlook |
Pipeline Potential | Explore Sarepta's diverse pipeline beyond DMD, including promising treatments for LGMD and other rare neuromuscular diseases |
Market Dynamics | Uncover Sarepta's competitive landscape, strategic partnerships, and potential threats from emerging therapies in the muscular dystrophy market |
Financial Trajectory | Analyst price targets range from $21 to $210, reflecting diverse views on Sarepta's future prospects amid current challenges and long-term growth potential |
Sarepta Therapeutics Inc Earnings Call Summary for Q2/2026
- Sarepta Q2 2026 EPS of $0.64 beat estimates by 191%, though revenue fell 34% YoY to $401.3M on weak ELEVIDYS gene therapy demand.
- Company narrowed 2026 product revenue guidance to $1.2B-$1.3B from $1.2B-$1.4B; expects Q3 ELEVIDYS sales below Q2 levels.
- Non-GAAP operating expenses cut sharply to $800M-$850M range; collaboration revenue raised $75M on higher Roche manufacturing income.
- Cash position strengthened to $945M, up $197M sequentially; management cites improved ELEVIDYS enrollment trends despite revenue lag.
- Shares rose 2.76% after hours to $16.37 following earnings beat; cohort 8 sirolimus data expected Q1 2027 amid ongoing regulatory reviews.
Last Updated: 06-08-2026, 03:40 am
Read Full TranscriptEarnings
Latest Release
05-08-2026
EPS / Forecast
0.64 / 0.22
Revenue / Forecast
401.3M / 383M
Compare SRPT to Peers and Sector
Metrics to compare | SRPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSRPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.0x | 7.6x | −0.4x | |
PEG Ratio | 0.11 | 0.30 | 0.00 | |
Price/Book | 1.2x | 1.2x | 2.6x | |
Price / LTM Sales | 0.9x | 1.8x | 3.1x | |
Upside (Analyst Target) | 19.2% | 24.4% | 48.8% | |
Fair Value Upside | Unlock | 20.6% | 5.7% | Unlock |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Sarepta (SRPT) Share Price Today?
The Sarepta share price today is 16.78.
What is the current Sarepta (SRPT) share price and day range?
As of 09-08-2026, the Sarepta share price is 16.78, with a previous close of 16.78. The share price has ranged from 16.47 to 17.26 today, while the 52-week range spans from 14.68 to 25.32.
What Is the Sarepta Market Cap?
As of today, Sarepta market cap is 1.77B.
What Is the Sarepta (SRPT) Share Price Target?
The average 12-month share price target for Sarepta is 22.09, with a high estimate of 38 and a low estimate of 5. 8 analysts recommend buying, while 5 suggest selling, with an overall rating of Neutral and +31.63% Upside potential.
What Is Sarepta's Earnings Per Share (TTM)?
The Sarepta EPS (TTM) is -1.32.
When Is the Next Sarepta Earnings Date?
Sarepta will release its next earnings report on 04-11-2026.
From a Technical Analysis Perspective, Is SRPT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Sarepta Trade On?
Sarepta is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Sarepta?
The stock symbol for Sarepta is "SRPT."
How Many Times Has Sarepta Stock Split?
Sarepta has split 1 times.
How Many Employees Does Sarepta Have?
Sarepta has 835 employees.
What Is the SRPT Premarket Price?
SRPT's last pre-market stock price is 16.90. The pre-market share volume is 18,770.00, and the stock has changed by 0.12, or 0.72%.
What Is the SRPT After Hours Price?
SRPT's last after hours stock price is 16.68, the stock has changed by -0.10, or -0.60%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.